Maxonis

About Maxonis

Maxonis has developed AGRG-based technology that effectively promotes nerve regeneration in patients with spinal cord injuries and peripheral nerve injuries, addressing the critical need for effective treatments in these areas. This patented solution has shown significant improvements in nerve repair outcomes during pre-clinical trials, offering a safer and simpler surgical procedure for patients with large nerve gaps.

```xml <problem> Spinal cord injuries and peripheral nerve injuries often result in nerve damage that is difficult to repair, leading to limited treatment options and a reduced quality of life for affected individuals. Current treatments for large nerve gaps can be complex and carry significant surgical risks, while effective solutions for spinal cord injury repair remain elusive. </problem> <solution> Maxonis is developing an AGRG-based technology designed to promote nerve regeneration in patients with spinal cord injuries (SCI) and peripheral nerve injuries (PNI). Their approach aims to address the unmet need for effective and safe nerve repair solutions, particularly for patients with large nerve gaps. Pre-clinical trials suggest that the AGRG-based treatment can significantly improve axonal growth in SCI and enhance nerve repair outcomes in PNI, offering a simpler surgical procedure with minimized risks. </solution> <features> - AGRG-based technology to promote nerve regeneration. - Treatment designed for both spinal cord injuries (SCI) and peripheral nerve injuries (PNI). - Addresses the challenge of repairing large nerve gaps. - Aims to offer a simpler surgical procedure compared to existing methods. - Pre-clinical trials have demonstrated significant improvements in nerve regeneration and axonal growth. </features> <target_audience> The primary target audience includes patients with spinal cord injuries and peripheral nerve injuries, as well as surgeons and medical professionals specializing in nerve repair and regeneration. </target_audience> ```

What does Maxonis do?

Maxonis has developed AGRG-based technology that effectively promotes nerve regeneration in patients with spinal cord injuries and peripheral nerve injuries, addressing the critical need for effective treatments in these areas. This patented solution has shown significant improvements in nerve repair outcomes during pre-clinical trials, offering a safer and simpler surgical procedure for patients with large nerve gaps.

Where is Maxonis located?

Maxonis is based in Center, Israel.

When was Maxonis founded?

Maxonis was founded in 2023.

Who founded Maxonis?

Maxonis was founded by Lilach Weisz and Itay Itzhaky.

  • Lilach Weisz - Co-founder & CEO
  • Itay Itzhaky - CEO & Co-founder
Location
Center, Israel
Founded
2023
Employees
8 employees
Looking for specific startups?
Try our free semantic startup search

Maxonis

Score: 41/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Maxonis has developed AGRG-based technology that effectively promotes nerve regeneration in patients with spinal cord injuries and peripheral nerve injuries, addressing the critical need for effective treatments in these areas. This patented solution has shown significant improvements in nerve repair outcomes during pre-clinical trials, offering a safer and simpler surgical procedure for patients with large nerve gaps.

maxonis.com50+
Founded 2023 – Center, Israel

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Team (5+)

Lilach Weisz

Co-founder & CEO

Itay Itzhaky

CEO & Co-founder

Company Description

Problem

Spinal cord injuries and peripheral nerve injuries often result in nerve damage that is difficult to repair, leading to limited treatment options and a reduced quality of life for affected individuals. Current treatments for large nerve gaps can be complex and carry significant surgical risks, while effective solutions for spinal cord injury repair remain elusive.

Solution

Maxonis is developing an AGRG-based technology designed to promote nerve regeneration in patients with spinal cord injuries (SCI) and peripheral nerve injuries (PNI). Their approach aims to address the unmet need for effective and safe nerve repair solutions, particularly for patients with large nerve gaps. Pre-clinical trials suggest that the AGRG-based treatment can significantly improve axonal growth in SCI and enhance nerve repair outcomes in PNI, offering a simpler surgical procedure with minimized risks.

Features

AGRG-based technology to promote nerve regeneration.

Treatment designed for both spinal cord injuries (SCI) and peripheral nerve injuries (PNI).

Addresses the challenge of repairing large nerve gaps.

Aims to offer a simpler surgical procedure compared to existing methods.

Pre-clinical trials have demonstrated significant improvements in nerve regeneration and axonal growth.

Target Audience

The primary target audience includes patients with spinal cord injuries and peripheral nerve injuries, as well as surgeons and medical professionals specializing in nerve repair and regeneration.